Today the United States Patent and Trademark Office issued U.S. patent number 11,464,892 to AllVascular which broadly covers the AVAS® device and methods for treating solid tumors. The granting of the AVAS® patent in the U.S. is a significant milestone for the Company and expands on two other patents granted in Australia and New Zealand. For this same patent family, applications are still pending in Brazil, China, Japan, Israel, and Europe. This patent will provide protection for the AVAS® out to 2036. The Company also has international filings for the AVAS® covering future improvements and iterations in a 2020 and 2021 PCT filing which are pending in Australia, New Zealand, United States, Canada, China, India, Israel, Japan, Korea, and Europe.